{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:18:18Z","timestamp":1773296298607,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.antiviral.2012.06.007","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T20:51:15Z","timestamp":1340830275000},"page":"207-211","source":"Crossref","is-referenced-by-count":2,"title":["Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment"],"prefix":"10.1016","volume":"95","author":[{"given":"Miguel","family":"Genebat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildefonso","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Concepci\u00f3n","family":"Romero-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Gonz\u00e1lez-Serna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ferrando-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kawthar","family":"Machmach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda M.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa \u00c1ngeles","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezequiel","family":"Ruiz-Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2012.06.007_b0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus efavirenz, both in combination with zidovudine\u2013lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection","volume":"201","author":"Cooper","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.06.007_b0010","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/jmv.21425","article-title":"Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools","volume":"81","author":"Chueca","year":"2009","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2012.06.007_b0015","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm1319","article-title":"Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1","volume":"11","author":"F\u00e4tkenheuer","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2012.06.007_b0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jac\/dkp293","article-title":"Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients","volume":"64","author":"Genebat","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2012.06.007_b0025","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/157016210793499295","article-title":"Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice","volume":"8","author":"Genebat","year":"2010","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.antiviral.2012.06.007_b0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.antiviral.2010.11.015","article-title":"Discordance rates between Trofile\u00ae test and short-term virological response to maraviroc","volume":"89","author":"Genebat","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.06.007_b0035","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/jac\/dkq379","article-title":"A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism","volume":"65","author":"Gonz\u00e1lez","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2012.06.007_b0040","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1128\/JCM.00953-10","article-title":"TROCAI (Tropism coreceptor assay information): a new phenotypic tropism test and its correlation with TROFILE-ES and genotypic approaches","volume":"48","author":"Gonz\u00e1lez-Serna","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2012.06.007_b0045","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1128\/AAC.00507-12","article-title":"HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients","volume":"56","author":"Gonz\u00e1lez-Serna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.06.007_b0050","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1128\/AAC.05857-11","article-title":"Correlation of the virological response to short-term maraviroc monotherapy with standard and deep sequencing-based genotypic tropism methods","volume":"56","author":"Gonz\u00e1lez-Serna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.06.007_b0055","unstructured":"Gulick, R.M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., Montana, J.B., McHale, M., Sullivan, J., Ridgway, C., Felstead, S., Dunne, M.W., van der Ryst, E., Mayer H., MOTIVATE Study Teams. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection, N Engl J Med 359, 1429-1441."},{"key":"10.1016\/j.antiviral.2012.06.007_b0060","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1086\/592052","article-title":"Phase II study of vicriviroc versus efavirenz (both with zidovudine\/lamivudine) in treatment-naive subjects with HIV-1 infection","volume":"198","author":"Landovitz","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.06.007_b0065","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/jac\/dkp063","article-title":"Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists","volume":"63","author":"Poveda","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2012.06.007_b0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/QAI.0b013e31820a9ae4","article-title":"Durability and safety of a novel salvage therapy in R5-Tropic HIV-infected patients maraviroc raltegravir etravirine","volume":"56","author":"Nozza","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2012.06.007_b0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/QAD.0b013e32830ebcd4","article-title":"Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism","volume":"22","author":"Raymond","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2012.06.007_b0080","doi-asserted-by":"crossref","unstructured":"Recordon-Pinson, P., Souli\u00e9, C., Flandre, P., Descamps, D., Lazrek, M., Charpentier, C., Montes, B., Trabaud, M.A., Cottalorda, J., Schneider, V., Morand-Joubert, L., Tamalet, C., Desbois, D., Mac\u00e9, M., Ferr\u00e9, V., Vabret, A., Ruffault, A., Pallier, C., Raymond, S., Izopet, J., Reynes, J., Marcelin, A.G., Masquelier, B., ANRS AC11 Resistance Study Group. 2010. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc the ANRS Geno Tropism Study, Antimicrob. Agents Chemother. 54 3335\u20133340.","DOI":"10.1128\/AAC.00148-10"},{"key":"10.1016\/j.antiviral.2012.06.007_b0085","first-page":"94","article-title":"An enhanced-sensitivity trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: A review of analytical and clinical studies","volume":"3","author":"Reeves","year":"2009","journal-title":"J. Viral Entry"},{"key":"10.1016\/j.antiviral.2012.06.007_b0090","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2249.2004.02474.x","article-title":"Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART)","volume":"136","author":"Ruiz-Mateos","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.antiviral.2012.06.007_b0095","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1128\/AAC.00753-11","article-title":"Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors","volume":"55","author":"Ruiz-Mateos","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2012.06.007_b0100","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/QAD.0b013e3280f00f9f","article-title":"Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults","volume":"21","author":"Sch\u00fcrmann","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2012.06.007_b0105","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1128\/JVI.80.10.4909-4920.2006","article-title":"Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir","volume":"80","author":"Westby","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.06.007_b0110","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/AAC.00853-06","article-title":"Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 co-receptor tropism","volume":"51","author":"Whitcomb","year":"2007","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212001489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212001489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T10:07:24Z","timestamp":1561889244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354212001489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0166354212001489"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.06.007","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}